APPLICATION OF ERBISOL® ULTRAPHARM FOR THE TREATMENT OF PATIENTS WITH PANCREATIC CANCER
Zhylchuk A.V., Коrnilina Е.М., Kudryavets Yu.I., Maksymiak G.I., Nikolayenko A.N., Sozoniuk L.I.
Aim: to study the effectiveness of the use of Erbisol® Ultrapharm in the complex treatment of patients with pancreatic cancer (PC). Object and methods: 88 patients with PC in the Т2–4N0–1М0–1. 36 patients with mechanical obstructive obstruction of the biliary tract and duodenum have undergone surgical intervention according to indications. All patients received monochemotherapy with gemcitabine (1000 mg/m2, intravenously, 1-, 8-, 15-day, 4 courses at 28-day intervals). Control group — 42 patients received only monochemotherapy; main group — 46 patients received chemotherapy (CT) and Erbisol® Ultrapharm (intramuscularly; 16 cycles of 7 days: 5 days — 2 times a day (4 ml in the morning, 2 ml in the evening), 2 days — 1 time (2 ml in the evening). Two months after CT completion, 2 courses of support and rehabilitation with Erbisol® Ultrapharm were conducted. The standard clinical, laboratory and instrumental methods of examination of patients were used. The observation time was 1 year. The efficacy of Erbisol® Ultrapharm was assessed by the levels of objective tumor response, the duration of the period of disease stabilization and survival of patients, the characteristics of their quality of life, and the parameters of toxicity. Results: the inclusion of Erbisol® Ultrapharm in basіс therapy contributed to improve the parameters clinical symptoms, reduced the effects of CT, decreased the severity of subjective complaints, improved quality of life for patients (Karnovsky-index in patients main group: 67.8% — before treatment and 70.0% — at the end of the investigation; in the control group — 67.9% and 60.0%, respectively). Partial regression of the primary tumor was noted in 39.1% in the main group and in 19.1% in the control group (p < 0.05). The duration of disease stabilization and overall survival were significantly higher in the main group compared with the control group (p < 0.05). Conclusion: the use of the drug Erbisol® Ultrapharm allowed to increase the effectiveness of treatment and to reduce the toxicity of CT of patients with PC stage T2–4N0–1M0–1.
No comments » Add comment